Kyverna Therapeutics, Inc.
KYTX
$1.86
$0.031.64%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.69% | -19.75% | -7.90% | -29.16% | -- |
| Total Depreciation and Amortization | 0.90% | 5.28% | 9.96% | 4.33% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -114.18% | 484.52% | -112.28% | 298.74% | -- |
| Change in Net Operating Assets | -99.35% | 19.17% | 339.83% | -282.16% | -- |
| Cash from Operations | -34.82% | -13.71% | 5.29% | -37.50% | -66.75% |
| Capital Expenditure | -421.57% | 90.08% | -89.32% | -62.57% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3,724.42% | 101.16% | 45.32% | -482.12% | -- |
| Cash from Investing | 4,222.78% | 101.00% | 44.73% | -487.86% | 158.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.07% | -2.54% | -2.16% | -5.48% | -- |
| Issuance of Common Stock | -64.44% | 23.29% | -99.98% | 123,985.45% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 86.26% | -98.32% | -- |
| Cash from Financing | -41.45% | 73.29% | -100.17% | 23,673.85% | -104.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.13% | 70.90% | -148.86% | 1,523.12% | 138.36% |